Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: A mechanistic study

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 11, 2010, Pages 5028-5036

  Bonadonna, Riccardo C ^a   Heise, Tim ^b   Arbet Engels, Christophe ^d   Kapitza, Christoph ^b   Avogaro, Angelo ^e   Grimsby, Joe ^d   Zhi, Jay ^d   Grippo, Joseph F ^d   Balena, Raffaella ^c  

^a UNIVERSITY OF VERONA   (Italy)

^b Profil   (Germany)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d University of Padova ^*

^e UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOKINASE; GLUCOSE; PIRAGLIATIN; PLACEBO; TRACER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; B LYMPHOCYTE; CELL FUNCTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; LYMPHOCYTE FUNCTION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANIMALIA;

EID: 78049512890     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-1041     Document Type: Article

References (38)

1. Wilson JE 2003 Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function. J Exp Biol 206:2049-2057
2. Iynedjian PB 2009 Molecular physiology of mammalian glucokinase. Cell Mol Life Sci 66:27-42
3. Matschinsky FM 2005 Glucokinase, glucose homeostasis, and diabetes mellitus. Curr Diab Rep 5:171-176 (Pubitemid 41599941)
4. Agius L 2008 Glucokinase and molecular aspects of liver glycogen metabolism. Biochem J 414:1-18
5. Levin BE 2006 Metabolic sensing neurons and the control of energy homeostasis. Physiol Behav 89:486-489 (Pubitemid 44634575)
6. Matschinsky FM 1996 Banting Lecture 1995. A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm. Diabetes 45:223-241
7. Osbak KK, Colclough K, Saint-Martin C, Beer NL, Bellanné-Chantelot C, Ellard S, Gloyn AL 2009 Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia. Hum Mutat 30:1512-1526
8. Sayed S, Langdon DR, Odili S, Chen P, Buettger C, Schiffman AB, Suchi M, Taub R, Grimsby J, Matschinsky FM, Stanley CA 2009 Extremes of clinical and enzymatic phenotypes in children with hyperinsulinism caused by glucokinase activating mutations. Diabetes 58:1419-1427
9. Grimsby J, Berthel SJ, Sarabu R 2008 Glucokinase activators for the potential treatment of type 2 diabetes. Curr Top Med Chem 8:1524-1532
10. Matschinsky FM 2009 Assessing the potential of glucokinase activators in diabetes therapy. Nat Rev Drug Discov 8:399-416
11. Grimsby J, Sarabu R, Corbett WL, Haynes NE, Bizzarro FT, Coffey JW, Guertin KR, Hilliard DW, Kester RF, Mahaney PE, Marcus L, Qi L, Spence CL, Tengi J, Magnuson MA, Chu CA, Dvorozniak MT, Matschinsky FM, Grippo JF 2003 Allosteric activators of glucokinase: potential role in diabetes therapy. Science 301:370-373
12. Guertin KR, Grimsby J 2006 Small molecule glucokinase activators as glucose lowering agents: a new paradigm for diabetes therapy. Curr Med Chem 13:1839-1843
13. Pal M 2009 Medicinal chemistry approaches for glucokinase activation to treat type 2 diabetes. Curr Med Chem 16:3858-3874
14. Doliba N, Qin W, Najali H, Wilson D, Liu C, Grimsby J, Matschinsky FM Piragliatin, an allosteric activator of glucokinase, increases glucose-induced respiration and insulin release of pancreatic islets from type 2 diabetics. University of Pennsylvania Institute for Diabetes, Obesity, and Metabolism (IDOM)/Diabetes and Endocrinology Research Center (DERC) Spring Symposium, Philadelphia, PA, March 2010 (Poster n. 7)
15. Grimsby J 2009 Effects of glucokinase activators: form bench to bedside. Program of the 91st Annual Meeting of The Endocrine Society,, Washington, DC, 2009
16. Zhai S, Mulligan M-E, Grimsby J, Arbet-Engels C, Boldrin M, Balena R, Zhi J 2008 Phase I assessments of a novel glucokinase activator RO4389620 in healthy male volunteers. Diabetologia 51(Suppl. 1):S372 (Abstract 928)
17. Zhi J, Zhai S, Mulligan M-E, Grimsby J, Arbet-Engels C, Boldrin M, Balena R 2008 A novel glucokinase activator RO4389620 improved fasting and postprandial plasma glucose in type 2 diabetic patients. Diabetologia 51(Suppl. 1):S23 (Abstract 42)
18. 2006 Diagnosis and classification of diabetes mellitus. Diabetes Care 29(Suppl 1):S43-S48
19. Bonadonna RC, Groop LC, Zych K, Shank M, DeFronzo RA 1990 Dose-dependent effect of insulin on plasma free fatty acid turnover and oxidation in humans. Am J Physiol 259:E736-E750
20. Groop LC, Bonadonna RC, DelPrato S, Ratheiser K, Zyck K, Ferrannini E, DeFronzo RA 1989 Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. J Clin Invest 84:205-213
21. Avogaro A, Toffolo G, Valerio A, Cobelli C 1996 Epinephrine exerts opposite effects on peripheral glucose disposal and glucose-stimulated insulin secretion. A stable label intravenous glucose tolerance test minimal model study. Diabetes 45:1373-1378
22. Bruttomesso D, Pianta A, Mari A, Valerio A, Marescotti MC, Avogaro A, Tiengo A, Del Prato S 1999 Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients. Diabetes 48:99-105
23. Bonuccelli S, Muscelli E, Gastaldelli A, Barsotti E, Astiarraga BD, Holst JJ, Mari A, Ferrannini E 2009 Improved tolerance to sequential glucose loading (Staub-Traugott effect): size and mechanisms. Am J Physiol Endocrinol Metab 297:E532-E537
24. Mari A, Ferrannini E 2008 β-Cell function assessment from modelling of oral tests: an effective approach. Diabetes Obes Metab 10(Suppl 4):77-87
25. Cobelli C, Toffolo GM, Dalla Man C, Campioni M, Denti P, Caumo A, Butler P, Rizza R 2007 Assessment of β-cell function in humans, simultaneously with insulin sensitivity and hepatic extraction, from intravenous and oral glucose tests. Am J Physiol Endocrinol Metab 293:E1-E15
26. Barrett PH, Bell BM, Cobelli C, Golde H, Schumitzky A, Vicini P, Foster DM 1998 SAAM II: Simulation, Analysis, and Modeling Software for tracer and pharmacokinetic studies. Metabolism 47:484-492
27. Weiss R, Caprio S, Trombetta M, Taksali SE, Tamborlane WV, Bonadonna R 2005 β-Cell function across the spectrum of glucose tolerance in obese youth. Diabetes 54:1735-1743 (Pubitemid 40774888)
28. Mari A, Stojanovska L, Proietto J, Thorburn AW 2003 A circulatory model for calculating non-steady-state glucose fluxes. Validation and comparison with compartmental models. Comput Methods Programs Biomed 71:269-281
29. Tuomi T, Honkanen EH, Isomaa B, Sarelin L, Groop LC 2006 Improved prandial glucose control with lower risk of hypoglycemia with nateglinide than with glibenclamide in patients with maturity-onset diabetes of the young type 3. Diabetes Care 29:189-194
30. Mannucci E, Tesi F, Bardini G, Ognibene A, Petracca MG, Ciani S, Pezzatini A, Brogi M, Dicembrini I, Cremasco F, Messeri G, Rotella CM 2004 Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without type 2 diabetes. Diabetes Nutr Metab 17:336-342
31. Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V, Rungby J, Landau BR, Schmitz O 2004 One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and α- and β-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 53:1187-1194
32. Mari A, Nielsen LL, Nanayakkara N, DeFronzo RA, Ferrannini E, Halseth A 2006 Mathematical modeling shows exenatide improved β-cell function in patients with type 2 diabetes treated with met-formin or metformin and a sulfonylurea. Horm Metab Res 38:838-844
33. Xu L, Man CD, Charbonnel B, Meninger G, Davies MJ, Williams-Herman D, Cobelli C, Stein PP 2008 Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on β-cell function in patients with type 2 diabetes: a model-based approach. Diabetes Obes Metab 10:1212-1220
34. Balas B, Baig MR, Watson C, Dunning BE, Ligueros-Saylan M, Wang Y, He YL, Darland C, Holst JJ, Deacon CF, Cusi K, Mari A, Foley JE, DeFronzo RA 2007 The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab 92:1249-1255
35. Ahrén B, Holst JJ, Mari A 2003 Characterization of GLP-1 effects on β-cell function after meal ingestion in humans. Diabetes Care 26:2860-2864
36. Basu A, Dalla Man C, Basu R, Toffolo G, Cobelli C, Rizza RA 2009 Effects of type 2 diabetes on insulin secretion, insulin action, glucose effectiveness, and postprandial glucose metabolism. Diabetes Care 32:866-872
37. Chu CA, Fujimoto Y, Igawa K, Grimsby J, Grippo JF, Magnuson MA, Cherrington AD, Shiota M 2004 Rapid translocation of hepatic glucokinase in response to intraduodenal glucose infusion and changes in plasma glucose and insulin in conscious rats. Am J Physiol Gastrointest Liver Physiol 286:G627-G634
38. Fyfe MC, White JR, Taylor A, Chatfield R, Wargent E, Printz RL, Sulpice T, McCormack JG, Procter MJ, Reynet C, Widdowson PS, Wong-Kai-In P 2007 Glucokinase activator PSN-GK1 displays enhanced antihyperglycaemic and insulinotropic actions. Diabetologia 50:1277-1287